Barclays
ACRV icon

Barclays’s Acrivon Therapeutics ACRV Stock Holding History

Barclays’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12.2K Sell
5,945
-1,409
-19% -$2.68K ﹤0.01% 4810
2026
Q2 		$13.1K Buy
7,354
+1,414
+24% +$2.4K ﹤0.01% 4664
2026
Q1 		$8.26K Sell
5,940
-18,462
-76% -$32.2K ﹤0.01% 4725
2025
Q4 		$58.8K Buy
24,402
+4,437
+22% +$9.6K ﹤0.01% 4713
2025
Q3 		$36.1K Sell
19,965
-960
-5% -$1.35K ﹤0.01% 4846
2025
Q2 		$24.9K Sell
20,925
-11,773
-36% -$16.2K ﹤0.01% 4816
2025
Q1 		$66.4K Sell
32,698
-5,393
-14% -$29K ﹤0.01% 4533
2024
Q4 		$229K Buy
38,091
+4,785
+14% +$34.8K ﹤0.01% 4243
2024
Q3 		$233K Buy
33,306
+11,273
+51% +$88.8K ﹤0.01% 4219
2024
Q2 		$128K Buy
22,033
+709
+3% +$5.71K ﹤0.01% 3790
2024
Q1 		$152K Sell
21,324
-3,160
-13% -$14.7K ﹤0.01% 4248
2023
Q4 		$120K Buy
24,484
+10,384
+74% +$54.8K ﹤0.01% 4593
2023
Q3 		$135K Sell
14,100
-163
-1% -$1.88K ﹤0.01% 3476
2023
Q2 		$185K Sell
14,263
-2,720
-16% -$32.9K ﹤0.01% 3283
2023
Q1 		$216K Buy
16,983
+12,841
+310% +$216K ﹤0.01% 3745
2022
Q4 		$47.7K Buy
+4,142
New +$52.6K ﹤0.01% 4569

Other funds holding ACRV

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
AAF Wealth Management
AAF Wealth Management Westborough, Massachusetts $275M AUM 17.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Redwood Park Advisors
Redwood Park Advisors Redwood City, California $157M AUM 7.34% 1-Year Est. Return

Barclays's ACRV Position: Q3 2026 in Review

Barclays reduced its Acrivon Therapeutics (ACRV) stake by 19% in Q3 2026, selling an estimated $2.68K and leaving 5,945 shares worth $12.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4810.

Barclays first reported a position in ACRV in Q4 2022 and has held it in 16 quarters since. The position peaked at $233K in Q3 2024. 14 funds tracked by Wall St. Rank hold ACRV as of Q3 2026.

  • Barclays held 5,945 shares of Acrivon Therapeutics worth $12.2K as of Q3 2026.
  • Barclays sold 1,409 Acrivon Therapeutics shares in Q3 2026, an estimated $2.68K.
  • Acrivon Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4810 holding.
  • Barclays first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 16 quarters since.
  • Barclays's Acrivon Therapeutics position peaked at $233K in Q3 2024.
  • 14 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.